Temozolomide-related hematologic toxicity.
Temozolomide (TMZ) is an oral alkylating agent used for the treatment of recurrent or newly diagnosed malignant gliomas with significant survival benefit. TMZ is generally well tolerated and safe. The most common side effects are mild to moderate, and are represented by fatigue, nausea, vomiting, thrombocytopenia, and neutropenia. However severe hematologic adverse events (HAEs), including myelodysplastic syndrome and aplastic anemia, have also been reported. In this review we present an overview of the available literature of HAEs after exposure to TMZ.
Department of Radiation Oncology, St Andrea Hospital, University Sapienza, Rome, Italy.
Claudia
C
Scaringi
Vitaliana
V
De Sanctis
Giuseppe
G
Minniti
Riccardo Maurizi
RM
Enrici
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D015897:Comorbidity; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology*; D019317:Evidence-Based Medicine; D006402:Hematologic Diseases / Q000453:epidemiology*; D006801:Humans; D015994:Incidence; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology*; D012307:Risk Factors; D000077204:Temozolomide; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide